MYC and neoplasm: In a mouse colorectal cancer model, lonidamine enhanced the infection and tumor-killing effects of the M1 virus by inhibiting myeloproliferative proto-oncogene (MYC), which not only reveals that lonidamine is a potential synergist of the M1 virus but also implies that MYC deficiency is a potential selective biomarker of M1 virus oncolytic efficacy (Cai et al., 2020).